- Foundational Databases: Resources like GenBank and Ensembl provide the essential blueprints for understanding how mutations affect human health.
- Precision Technologies: Next-generation sequencing (NGS) and single-cell sequencing allow for the identification of specific drug targets and personalized treatment monitoring.
- Population Insights: Biobanks and patient registries facilitate large-scale studies to understand disease prevalence and treatment responses across diverse groups.
- Tailored Medicine: Pharmacogenomics and GWAS help predict how individuals will respond to specific drugs, reducing adverse reactions and increasing efficacy.
- Gene Editing: Functional genomics tools like CRISPR-Cas9 enable researchers to "edit" DNA to uncover the specific roles genes play in various conditions.
Genomic databases and the Human Genome Project
The Human Genome Project marked a turning point in genetic research as the first initiative to sequence the complete human genome. Led by an international consortium between 1990 and 2003, the project systematically mapped the DNA of a select set of organisms. The resulting data provided foundational information about the human genome, enabling scientists to understand how mutations in genes affect people and learn more about inherited diseases. This project was also one of the key steps toward developing genetically targeted medicines and more personalized treatments.
Several key genomic databases have since played a critical role in organizing and distributing genetic information. GenBank stores genetic sequences from a diverse range of organisms, providing a broad resource for comparative and disease-focused research. dbSNP focuses on single nucleotide polymorphisms, cataloging genetic variations associated with diseases. Ensembl provides a centralized resource for researchers studying the genomes of humans, other vertebrates, and model organisms. More recently, NCBI Datasets has emerged as a unified platform for finding, browsing, and downloading genomic sequences, annotations, and metadata across species. Together, these databases form the reference infrastructure that underpins target identification and variant interpretation in drug discovery.
Next-generation sequencing (NGS)
Next-generation sequencing (NGS) and other genetic analysis technologies help researchers identify and characterize the genetic variants associated with disease. NGS enables rapid sequencing of entire genomes or targeted panels, allowing teams to pinpoint disease-associated mutations with high resolution and throughput.
In drug discovery, NGS plays a critical role at multiple stages. It supports target identification by revealing variants linked to disease mechanisms. It informs patient stratification by identifying biomarkers that define eligible populations. And it enables pharmacogenomic analysis by connecting genetic profiles to drug response patterns. NGS is also used for multi-analyte tumor analysis and to develop new approaches for monitoring cancer treatment and recurrence.
As sequencing costs continue to decline, NGS is increasingly accessible for large-scale studies, making it a foundational technology for precision medicine programs.
Biobanks, patient registries, and population studies
Biobanks serve as repositories for genetic samples sourced from diverse populations. These collections facilitate large-scale genetic analyses that shed light on genetic diversity, disease prevalence, and treatment responses. Population studies also help to identify genetic variations associated with specific diseases across different ethnic groups.
Alongside biobanks, genetic patient registries are sophisticated databases designed to house comprehensive genetic and clinical information about patients with specific medical conditions. These databases act as purpose-driven collections of data, organized to serve predetermined scientific, clinical, or policy objectives. A registry can capture patients' clinical statuses, medical histories, laboratory results, and more. Some examples of patient registries might be those focused on rare diseases, cancer subtypes, or primary immune deficiencies. These registries are used to:
- Assist healthcare practitioners in formulating optimal treatment strategies for individual patients or specific groups.
- Provide data to develop therapeutics or to learn about population behavior patterns and their association with disease development
- Help develop research hypotheses
- Support quality healthcare and personalized treatments
Pharmacogenomics and precision medicine
Genetic differences between individuals influence how they metabolize and respond to medications. Pharmacogenomics explores the link between these genetic variations and drug responses, forming one of the foundational pillars of precision medicine.
By understanding how genetic variants affect drug efficacy and safety, pharmacogenomics enables more targeted treatment selection and dosing. This has direct implications for drug development: it allows sponsors to stratify patient populations, identify responders earlier, and reduce the risk of adverse events during trials. Since it's estimated that only 50% of patients respond positively to their medications and adverse drug reactions can be severe, identifying the genetic factors that predispose patients to negative outcomes is a meaningful lever for improving both trial success and clinical care.
There are some pharmacogenomic tests available at the moment, including HercepTest, which received approval from the Center for Devices and Radiological Health in 2001 to detect HER2 protein overexpression in breast cancer tissue. More advanced multigene solutions for breast cancer diagnosis are now emerging, such as the FDA-approved 70-gene-based MammaPrint. These tests guide long-term management decisions and help create tailored treatment plans. Cancer treatment is not the only area where pharmacogenomic testing is demonstrating value. The FDA currently includes pharmacogenomic information on the labels of approximately 200 medications. This information can help doctors tailor drug prescriptions for individual patients by providing guidance on dose, possible side effects, or differences in effectiveness for people with certain gene variants.
Examples of common medicines that have pharmacogenetic tests include:
- Abacavir: an HIV treatment
- Carbamazepine: an epilepsy treatment
- Tamoxifen: a breast cancer treatment
Genome-wide association studies (GWAS)
Genome-wide association studies (GWAS) scan the genomes of large populations to identify genetic markers associated with diseases. For example, some GWAS have identified single nucleotide polymorphisms (SNPs) associated with several complex conditions including diabetes, heart disease, Parkinson's disease, and Crohn's disease. These associations provide critical starting points for drug discovery, helping teams prioritize targets, define genetically stratified patient populations, and design inclusion criteria for precision trials.
Several GWAS resources are available online, and one of the largest is the GWAS catalogue, which is a structured repository of summary statistics for a large variety of traits. Other useful resources include the LD-hub, GWAS summary statistics from the UK Biobank and dbGaP, which allows access to individual genomic data for authorised users.
Functional genomics and CRISPR-Cas9
Functional genomics aims to understand how genes operate and contribute to biological processes, specifically by defining the relationship between an organism's genome and its phenotype. Several technologies are available to study functional genomics, one widely used approach is a gene editing technology called CRISPR/Cas9 or Clustered Regularly Interspaced Short Palindromic Repeat. This tool gives researchers the ability to change an organism's DNA by adding, removing or altering genetic material at particular locations in the genome. With the ability to “edit” genes, it is now possible to create libraries of CRISPR reagents covering the activation or deletion of every gene in the genome to help find the specific genes involved with conditions.
Single-cell sequencing
Single-cell sequencing allows researchers to analyze individual cells and characterize their unique gene expression profiles. This resolution enables a more granular understanding of disease mechanisms and supports the identification of suitable preclinical models for specific disease subtypes. Combining single-cell sequencing with CRISPR (scCRISPR screening) improves the precision of target confirmation and provides more mechanistic detail about how those targets function. In the same regard, single-cell sequencing allows researchers to learn more about how compounds affect specific cell types and uncover any unintended effects. In clinical development, single-cell sequencing helps:
- Find biomarkers to group patients
- Understand how drugs work
- Track how diseases and drug responses change
Conclusion
Genetic data is improving success rates, reducing costs, and compressing timelines across drug development. The collaborative use of genomic databases, sequencing technologies, biobanks, and functional genomics has made this possible. For sponsors designing precision medicine programs, understanding these data sources is not optional. It directly informs target selection, patient stratification, eligibility design, and long-term engagement strategy. The teams that integrate genetic data effectively across the development lifecycle are better positioned to identify the right patients, design viable protocols, and execute trials with fewer delays.
To learn more about the role of genomics in drug discovery, download our whitepaper.